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Abstract: Ventilator-associated pneumonia is the most common infection in intensive care 
unit patients associated with high morbidity rates and elevated economic costs; Pseudomonas 
aeruginosa is one of the most frequent bacteria linked with this entity, with a high attributable 
mortality despite adequate treatment that is increased in the presence of multiresistant strains, 
a situation that is becoming more common in intensive care units. In this manuscript, we review 
the current management of ventilator-associated pneumonia due to P. aeruginosa, the most recent 
antipseudomonal agents, and new adjunctive therapies that are shifting the way we treat these 
infections. We support early initiation of broad-spectrum antipseudomonal antibiotics in  present, 
followed by culture-guided monotherapy de-escalation when susceptibilities are available. Future 
management should be directed at blocking virulence; the role of alternative strategies such as 
new antibiotics, nebulized treatments, and vaccines is promising.
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Background
Ventilator-associated pneumonia (VAP) is the most common infection among the 
critically ill and the first cause of antibiotic prescription in intensive care units (ICUs), 
with an incidence of five to 20 cases per 1,000 mechanical ventilation (MV)-days and a 
global prevalence of 15.6%1–5 that has not changed significantly despite the implementa-
tion of care bundles. Episodes caused by multidrug-resistant (MDR) organisms, such 
as Pseudomonas aeruginosa are associated with significant attributable mortality;3,6 
VAP represents a major clinical and economical problem in critically ill patients due 
to its associated morbidity, prolonged MV-days, and ICU length of stay (LOS), which 
translates to elevated health care costs as high as US$40,000 per episode.7,8
P. aeruginosa (with Staphylococcus aureus) is one of the most common bacteria 
causing VAP,5,9 with a prevalence of approximately 4%,2 and its attributable mortal-
ity is as high as 13.5%, even with adequate antibiotic treatment.3 In MDR strains, 
mortality rises up to 35.8%, and the presence of MDR strains has been identified as 
an independent predictor of hospital death (adjusted odds ratio [AOR] 1.634, 95% 
confidence interval [CI]: 1.124–2.374) and is the single strongest predictor of initial 
inadequate antibiotic therapy (AOR 5.706, 95% CI: 3.587–9.077).5,9 A recent study by 
Micek et al demonstrated that P. aeruginosa VAP mortality has increased to 41.9%, with 
increased age and Charlson comorbidity score, inappropriate initial antibiotic therapy, 
and vasopressor use as independent predictors of mortality.10 Antibiotic resistance has 
been on the rise in the last decade,5,11–13 which is worrisome since P. aeruginosa is one 
of the three top microorganisms causing health care respiratory infection and is  resistant 
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to carbapenem,14 and, even in patients with early-onset VAP 
and no risk factors, MDR P. aeruginosa is frequent.15,16 
Among known risk factors for MDR P. aeruginosa in MV 
patients, the most frequent are antimicrobial therapy within 
90 days (51.9%) and current hospitalization of more than or 
equal to 5 days (45.3%).2 Infection by MDR P. aeruginosa 
is associated with worse outcomes with an excess mortality 
rate of 12 with a more than twofold increased risk of mor-
tality (relative risk [RR] 2.34, 95% CI: 1.53–3.57) and ICU 
LOS, compared to susceptible strains.11 In VAP caused by 
MDR P. aeruginosa,10,17 both prior antibiotic use and delayed 
effective antibiotic therapy in infection also negatively affect 
mortality and cost.5,18,19
P. aeruginosa serotypes causing VAP have different 
behavior; O6 and O11, the most common, are associated 
with a clinical resolution of 60%, and serotypes O1 and O2, 
represent less common strains, with higher mortality.16 Vallés 
et al performed an analysis of pulsed-field electrophoresis on 
more than 1,700 isolates of P. aeruginosa in ICU patients, 
identifying different genotypes. Clones that were responsible 
for colonization (skin, gut, and respiratory) least frequently 
caused pneumonia, and VAP’s resolution was frequent and 
uncomplicated. However, clones that were not related to 
prior colonization were associated with very high mortality 
rates.20 This observation may be associated with the expres-
sion of virulence factors in P. aeruginosa, such as type III 
secretory proteins.21
Most clonally related isolates caused gastric colonization 
before skin or respiratory tract colonization, suggesting an 
association with instillation of tap water used for medication 
by the oral route. A similar study conducted in two differ-
ent ICUs in a single hospital in France4 identified an MDR 
clone of P. aeruginosa in the sinks of 12 rooms. As a whole, 
from 26 cases of colonization/infection by P. aeruginosa, 
five were related to an exogenous colonization (environ-
mental colonization in four patients and cross-infection in 
one). These findings emphasize the fact that different risk 
factors may be implicated depending on whether the clone 
is from exogenous contamination or carried as endogenous 
colonization. Therefore, different infection control strategies 
should be applied to prevent colonization of patients with 
P. aeruginosa, including strategies to limit the potential of 
sinks to act as potential reservoirs.
Risk factors
Risk factors for P. aeruginosa in VAP are mainly prior anti-
biotic exposure and MV longer than 5 days.22–24 Patients with 
chronic obstructive pulmonary disease and other chronic 
respiratory diseases may carry endogenous colonization and 
can develop a severe respiratory infection following intubation 
and MV. Interestingly, risk factors in patients with P. aerugi-
nosa and prior antibiotic exposure are  different.25 P. aeruginosa 
is the first cause of pneumonia in the post operative period of 
lung transplant26 and in intubated patients with a prior epi-
sode of pneumonia.27 P. aeruginosa is also the most common 
pathogen in patients with health care-associated pneumonia 
who required ICU admission and further MV.28 
Current management
Latest guidelines for the antibiotic treatment of P.  aeruginosa 
VAP are the 2005 American Thoracic Society/Infec-
tious Diseases Society of America guidelines, which 
recommend combination therapy with antipseudomonal 
cephalosporin (cefepime, ceftazidime) or carbapenem 
(imipenem, meropenem, or β-lactam/β-lactamase inhibitor 
[piperacillin–tazobactam]) plus antipseudomonal fluoroqui-
nolone (ciprofloxacin or levofloxacin) or aminoglycoside.29 
 However, since their publication a decade ago, many find-
ings have been made in the field of antibiotic management 
in the critically ill, highlighting inappropriate treatment due 
to insufficient dosing and suboptimal antibiotic exposure, 
which are associated with increased mortality and worse 
outcomes.30–33 Furthermore, the rise of MDR strains in 
nosocomial pneumonia renders this approach outdated.12,34 
It is important to bear in mind that it is critical to avoid 
antibiotics to which the patient has been exposed over the 
last 30 days, since the new episodes usually are relapses of 
a strain with phenotypic variations and not reinfection. Also, 
recently, a multicenter study has shed some light regarding 
treatment failure in P. aeruginosa VAP. With an occurrence 
rate of approximately 30% of episodes, the study identi-
fied risk factors for failure, including age, chronic illness, 
limitation of life support, severity of illness, previous use 
of a fluoroquinolone, and bacteremia. Interestingly, neither 
antibiotic susceptibility patterns nor combination therapy 
influenced failure rates; on the other hand, treatment with 
a fluoroquinolone did decrease it.35 Figure 1 outlines initial 
P. aeruginosa VAP management.
To avoid suboptimal antibiotic management, we believe 
that a composite approach has to be made, taking into account 
variables other than the classic microbiological paradigm 
of appropriate antibiotic therapy based only in minimum 
inhibitory concentration (MIC)’s susceptibility patterns and 
tailoring treatment to each patient, assessing specific risk 
factors especially for MDR (Figure 1).36 The cornerstone 
for improving outcomes is timing; early effective therapy as 
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soon as possible might be the difference between death and 
successful treatment, especially when shock is present.37,38 
Appropriate empirical choice of agent is fundamental, as 
is the use of a broad-spectrum antibiotic based on local 
ecology followed by reassessment of clinical response and 
microbiological data at 48–72 hours.39,40 In P. aeruginosa VAP, 
empiric combination therapy with a β-lactam plus an amino-
glycoside has proved to be superior to monotherapy, reduc-
ing mortality up to 50% in many studies and meta- analyses, 
mainly due to appropriate initial therapy.40–42 However, there 
is no difference between one or two effective antibiotics, 
which is the rationale for de-escalating to monotherapy 
once microbiological results are available.42 De-escalation 
is a safe strategy and has to be done when possible, even in 
neutropenic patients.43 Regarding duration of therapy, many 
studies have demonstrated that 8 days of antibiotic for VAP 
is safe, reduces emergence of MDR and costs, and avoids 
unnecessary toxicity to the patient.44–47 However, in VAP 
caused by gram-negative bacilli, 8 vs 15 days of antibiotic is 
associated with increased pulmonary infection recurrence.45 
Since the aim of antibiotic therapy is pneumonia resolution 
and not P. aeruginosa eradication from the endotracheal tube/
tracheostomy biofilm, antibiotic courses longer than 10 days 
in patients with clinical cure only add MDR-strain selection. 
In P. aeruginosa VAP, patients with inappropriate empirical 
antibiotic therapy, clinical resolution (fever and hypoxemia) 
PA VAP
Anti-PA quinolone: Ciprofloxacin or
levofloxacin
Yes
Anti-PA β-lactam: Imipenem,
meropenem, or aztreonam (penicillin
allergy)     
Plus:
Clinical response
Anti-PA β-lactam: Piperacillin–tazobactam,
ceftazidime, cefepime 
No
Rapid diagnostic test
(Genexpert®, Filmarray®)
Positive for PA
Favorable
De-escalate according to
antimicrobial susceptibility results
Delayed resolution
Antibiotic PK/PD optimization:
• Extended/continuous infusions (β-lactams)
• Increase doses if augmented clearance suspected
Risk factors for MDR strains:
• ICU admission in the previous 90 days
• Antibiotic exposure in the previous 30 days
• COPD/cystic fibrosis/diabetes mellitus
• Presence of invasive devices
• Bedridden status
• Neutropenia
• Solid organ transplant recipient
Plus: Anti-PA quinolone or
aminoglycoside 
If high XDR
prevalence: Consider
inhaled colistin (high
dose) 
Plus: Anti-PA β-lactam or
aminoglycoside 
Aminoglycoside
Figure 1 Management of PA vAP.
Notes: Carbapenems are usually reserved for MDR or polymicrobial infections. Aminoglycosides should be avoided as monotherapy despite antimicrobial susceptibility given 
its poor performance in lung tissue. High-dose inhaled colistin: 5 million units every 8 hours.
Abbreviations: COPD, chronic obstructive pulmonary disease; MDR, multidrug-resistant; PA, Pseudomonas aeruginosa; PK/PD, pharmacokinetic/pharmacodynamic; vAP, 
ventilator-associated pneumonia; XDR, extensively drug resistant; ICU, intensive care unit.
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is delayed 8 days (median), as  happens with other MDR 
bacteria.46 Furthermore, longer antibiotic courses may be rec-
ommended for immunosupressed patients with initial inap-
propriate empirical therapy VAP caused by MDR/extensively 
drug-resistant strains without clinical resolution.47 Recently, 
biomarkers’ roles in antibiotic duration guidance have been 
the subject of multiple studies, with procalcitonin being the 
only one that has proved to be safe and reduce antibiotic days 
in VAP. When procalcitonin concentration is ,0.5 ng/mL 
or has decreased by $80% (compared with the first peak 
concentration), antibiotics can be discontinued even in very 
short-course therapy (3 days), irrespective of the severity of 
the infectious episode; however, in bacteremic patients, at 
least 5 days of therapy is recommended.48–50
Another point to consider is optimizing the choice of 
antimicrobial according to pharmacokinetic (PK)/pharma-
codynamic parameters. It is important to bear in mind that 
the antibiotic we choose has to reach therapeutic concentra-
tions at the site of infection, where the bacteria–antibiotic 
interaction takes place, in order to obtain bacterial clearance 
as soon as possible.51 Also, administration of a loading dose 
and administration of β-lactams in extended and continuous 
infusions increases antibiotic exposure and the probability 
of PK target attainment, which is essential in cases of septic 
shock, obesity, burn patients, and intermediate-resistant 
P. aeruginosa strains,32 and it is associated with decreased 
14-day mortality, faster recovery, and shorter ICU LOS and 
duration of treatment.52–64 With this in mind, nebulized antibi-
otic administration in MV may increase alveolar penetration 
compared with IV administration.47 Nebulized colistin (high 
dose) in monotherapy has been studied in a small-randomized 
trial and a retrospective study, and noninferiority to IV com-
bination therapy has been reported.65–67 This approach is very 
interesting since it enables delivery of high concentrations of 
the antibiotic with minimal absorption and marginal systemic 
levels, which could be a turning point in cases of MDR strains 
where available drugs are highly toxic.  Effective treatment 
of VAP caused by MDR organisms such as P. aeruginosa 
and Acinetobacter baumannii has been reported with high-
dose nebulized colistin, even achieving airway eradication.65 
 Currently, a few agents are available for nebulization (colistin, 
tobramycin, aztreonam, ceftazidime, and amikacin) but are 
required to be tested in randomized clinical trials to know the 
safety and what adds to standard therapy. Further research 
and evidence-based guidelines are required. Other nebu-
lized agents such as hypertonic saline and N-acetylcysteine, 
sometimes used as coadjutant therapy in the treatment of 
P. aeruginosa lung infection in cystic fibrosis patients, are still 
controversial, without strong evidence supporting or advice 
against its use in VAP treatment.68–72
New antibiotic treatments
Cephalosporins
Proven efficacy, broad spectrum (some of them including 
P. aeruginosa), and a well-characterized PK/pharmacody-
namic profile, in addition to a favorable safety profile, make 
this antimicrobial class play an important role in nosocomial 
infection treatment, including VAP.73 In response to the 
emergence of nosocomial infections due to β-lactam-resistant 
gram-negative bacteria in recent years, two strategies have 
been developed to improve their coverage: the development 
of new β-lactam molecules with the capacity to evade some 
mechanisms expressed by resistant bacteria and the addition 
of novel compounds capable of inactivating β-lactamases.74
Ceftobiprole (BAL9141)
Ceftobiprole medocaril has enhanced activity against gram-
negative pathogens, including Escherichia coli, Klebsiella 
pneumoniae, A. baumannii, and other Enterobacteriaceae; its 
antipseudomonal in vitro activity is similar to that of cefepime, 
and P. aeruginosa cross-resistance between ceftobiprole and 
other antipseudomonal cephalosporins has been reported.75,76 
Also, it is inactive against bacteria expressing extended-
spectrum β-lactamase (ESBL).75,76 Its bactericidal activity 
also acts against gram-positive bacteria, including resistant 
Streptococcus pneumoniae, methicillin-resistant S. aureus, 
and Enterococcus faecalis, but not against Enterococcus 
faecium.78 Its activity against some of the ESKAPE patho-
gens and its stability against a wide range of β-lactamases 
(not KPC) make it an attractive option for hospital-acquired 
pneumonia treatment. A total of 781 patients were included in 
a Phase III study, 210 of whom had VAP. Clinical cure rates 
overall were 49.9% and 52.8% for ceftobiprole and ceftazi-
dime/linezolid, respectively. However, while the cure rates 
were not different in nosocomial pneumonia, ceftobiprole per-
formed worse on VAP (23.1% vs 36.5 cure rate). In contrast, 
those patients who had to be ventilated because of worsening 
of the pneumonia had a better outcome with ceftobiprole 
than with ceftazidime/linezolid (Table 1).77 These findings 
might be associated with increases in distribution volume in 
septic patients receiving sedation to start MV, which cannot 
be anticipated using Monte Carlo simulation.
Ceftazidime–avibactam
Ceftazidime is a well-known antipseudomonal cepha-
losporin, also active against other gram-negative bacilli and 
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 gram-positive cocci and playing an important role in the 
treatment of nosocomial infections; however, it is suscep-
tible to degradation due to β-lactamases, especially those 
of Ambler class A and C. Avibactam (NXL 104), recently 
added to the three approved β-lactamase inhibitors, is a mol-
ecule capable of avoiding the activity from A-, B-, and some 
D-class β-lactamases, including AmpC, KPC (Klebsiella 
pneumoniae carbapenemase), and ESBL.73,74,78,79 Despite 
not having antibacterial activity, its union with ceftazidime 
protects it from degradation from β-lactamases, enhancing its 
activity against Enterobacteriaceae producing β-lactamases, 
including P. aeruginosa.79,80 In a murine model, ceftazidime–
avibactam has shown good penetration of epithelial lining 
fluid and effectiveness against P. aeruginosa with an MIC 
up to 32 µg/mL.81  Ceftazidime–avibactam exhibits a great in 
vitro MIC50/90 reduction against P. aeruginosa  producing 
β-lactamases compared with ceftazidime alone and also 
shows activity against some meropenem-non-susceptible 
strains in catheter-associated urinary tract infection.74,82,83 
Phase II trials with ceftazidime avibactam have shown 
favorable results, a good safety profile, and have been well 
tolerated when used alone for complicated urinary infec-
tions, and when used with metronidazol for intra-abdominal 
 infections.84,85 Its role in nosocomial pneumonia is actually 
being analyzed in a Phase III study (Table 1).86 Caution should 
be taken into account in countries/ institutions where the main 
resistance problem is OXA-48, and consideration given to 
the need for initial loading dose, to avoid the potential risk 
of initial underdosing, particularly in those patients with 
decreased creatinine clearance.
Ceftolozane–tazobactam (CXA-201)
Like other cephalosporins, ceftolozane develops its bac-
tericidal activity by inhibiting the cell wall synthesis via 
penicillin-binding proteins; particularly, ceftolozane has 
shown an enhanced affinity for these proteins in comparison 
with β-lactams.87 In vitro studies suggest it is not affected by 
some β-lactam resistance mechanisms expressed by P. aerugi-
nosa, such as efflux pumps or reduced wall permeability due 
to porin channel mutations,88,89 making it the most active 
antipseudomonal β-lactam.90,91 However, by itself it does not 
have activity against β-lactamase-producing strains. Tazobac-
tam’s activity against β-lactamases bring to ceftolozane the 
potential to eliminate many resistant strains of P. aeruginosa 
and other β-lactamase-producing gram-negative bacteria.92 
A Phase III trial has shown ceftolozane–tazobactam’s effi-
cacy in complicated intra-abdominal infections in combina-
tion with metronidazole, including those caused by MDR 
Table 1 Studies regarding the effect of new antibiotics on Pseudomonas aeruginosa infection
Authors/ 
sponsors
Year Type of study Number  
of patients
Interventions Results
Awad et al77 2014 Randomized,  
double-blind,  
multicenter
781 Ceftobiprole vs  
ceftazidime + linezolid
Clinical cure, % (95% CI): 
HAP (excluding vAP): 77.8% vs  
76.2% (-6.9 to 10) 
vAP: 37.7% vs 55.9% (-36.4 to -0)
vazquez et al84 2012 Prospective, Phase II,  
randomized,  
investigator-blinded
135 Ceftazidime–avibactam vs  
imipenem–cilastatin
Favorable microbiological  
response, % (95% CI): 
70.4 vs 71.4 (-27.2 to 25)
AstraZeneca86 Ongoing Phase III, randomized,  
multicenter, double-blind,  
double-dummy,  
parallel-group, comparative
Recruiting* Ceftazidime–avibactam vs  
meropenem
Ongoing
Solomkin et al92 2015 Prospective, randomized, 
double-blind
993 Ceftolozaneztazobactam +  
metronidazole vs meropenem
Clinical cure, % (95% CI): 
83% vs 87.3% (-8.91 to 54)
Calixa  
Therapeutics,  
Inc94
2009 Multicenter, double-blind, 
randomized, Phase II
127 Ceftolozane–tazobactam vs  
ceftazidime
Favorable microbiological  
response, % (95% CI): 
83.1 (71.7–91.2 ) vs  
76.3 (59.8–88.6)
Cubist  
Pharmaceuticals 
Holdings LLC95
Ongoing Multicenter, open-label, 
randomized
Recruiting* Ceftolozane–tazobactam vs  
piperacillin–tazobactam
Ongoing
Polyphor Ltd100 Ongoing Phase II, open-label, 
multicenter
Recruiting* POL7080 coadministered  
with standard of care
Ongoing
Notes: *Patient numbers for the ongoing studies are not yet available, however, the estimated patient enrollment numbers are 850 for the AstraZeneca trial, 728 for the 
Cubist trial, and 25 for the Polyphor Ltd trial.
Abbreviations: CI, confidence interval; HAP, hospital-associated pneumonia; VAP, ventilator-associated pneumonia.
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 pathogens,93 and a Phase II trial also demonstrated its efficacy 
in  complicated urinary tract infection treatment.94 Currently, 
a Phase III study is evaluating its safety and efficacy in VAP 
(Table 1).95
Arbekacin
Arbekacin is an aminoglycoside discovered in the 1970s and 
has been used in many countries for more than 2 decades. 
Usually indicated in the treatment of infections caused by 
methicillin-resistant S. aureus, it has also shown activity 
against gram-negative pathogens, including Pseudomonas 
spp. Its capacity to be unaltered by many of the aminoglyco-
side-modifying enzymes, one of the most frequent ways by 
which aminoglycosides are inactivated, confers to arbekacin 
enhanced activity against P. aeruginosa resistant to amikacin, 
gentamicin, and tobramycin.93,96 In vitro analysis suggests 
that arbekacin in combination with aztreonam is an effective 
regimen against MDR P. aeruginosa, including metallo-β-
lactamase-producing strains;93 however, further studies are 
needed to show its applicability and safety in clinical practice. 
In PK studies, arbekacin has shown acceptable pulmonary 
tissue distribution and an adequate safety profile;97 however, 
therapeutic plasma level monitoring is recommended to 
optimize its efficacy and minimize adverse effects, mainly 
nephrotoxicity.93
POL7080
POL7080 is a novel peptidomimetic antibiotic with proven 
activity against P. aeruginosa in murine models.98 Its 
mechanism of action is not totally clear, but it is known that 
it modifies the lipopolysaccharide-assembling of the bacte-
rial outer membrane via the lipopolysaccharide-assembling 
protein LptD.98 A Phase I study has shown POL7080 to be 
safe and well tolerated,99 and actually a Phase II study is 
evaluating its safety and efficacy in patients with VAP due to 
P. aeruginosa (Table 1).100 Nephrotoxicity is a major concern 
with this drug.
Pathogenicity and newer  
adjunctive therapies
Pathogenicity
P. aeruginosa’s pathogenicity is very complex,101–103 and 
a detailed analysis is far from the objective of this report. 
During a host’s infection process, P. aeruginosa uses pili, 
flagella, and fimbriae, a series of functional elements, to 
move and adhere on living and nonliving surfaces, such as 
different tissues and medical devices,104,105 and also employs 
these mobile elements to form bacterial  communities 
based on an intricate intercellular communication mecha-
nism (ie, quorum sensing), many times surrounded by a 
 polysaccharide-based structure known as biofilm. This 
structure is produced by the bacterial colony and acts as a 
barrier against different chemical factors and physical forces 
(eg, immune system response and antibiotics), providing a 
favorable environment for colony survival and playing an 
important role in its permanency and in the chronic coloni-
zation/infection process.21,104,106,107
Many of the steps in the biofilm formation process are 
being highly investigated as treatment targets, with many 
others not being completely understood yet.21
Alginate is a very important virulence variable, affect-
ing children with cystic fibrosis.108,109 However, cystic 
fibrosis patients carry mucosal strains110 which are uncom-
mon in patients with VAP, requiring different therapeutic 
considerations.
Quorum sensing
Quorum sensing is an evolved adaptive strategy expressed 
in several gram-negative and gram-positive bacteria species, 
based on a highly complex cell-to-cell communication mech-
anism, which allows a group of bacteria to exchange informa-
tion and make dynamic and coordinated changes in response 
to different environmental stimuli, thus playing an important 
role in host infection and the bacterial permanence.111 This 
system is based on signal molecules expressed by bacteria 
in a density-dependent way and released to the environment; 
these molecules are called autoinducers and are recognized 
by other cells, in some cases from different species (eg, 
between P. aeruginosa and Burkholderia cepacia), inducing 
genomic changes and giving to a population of bacteria the 
ability to deploy coordinated responses to affront different 
environmental assaults.111–113 With three known autoinducers 
from the acyl-homoserine lactone (AHL) family, Las, Rhl, 
and the P. aeruginosa quinolone signal, P. aeruginosa has 
one of the most classical and understood quorum sensing 
models, involved in many defense mechanisms such as bio-
film formation and production of antimicrobial substances 
and bacterial virulence factors.21,111,112,114 This communication 
system facilitates host infection, ensures the permanency of 
colonies, and makes eradication of these colonies difficult, 
making it a highly attractive target for novel treatments. Three 
targets in this communication circuit have been identified as 
susceptible to pharmacological intervention: the inhibition 
of both Las and Rhl synthesis, the autoinducers’ degrada-
tion, and the blockage of AHL receptor function,21,111,115 
with several in vitro and animal model trials demonstrating 
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the blockade of the quorum sensing as a feasible strategy to 
reduce the bacterial virulence and restore some P. aerugi-
nosa susceptibility to classical antibiotics. However, further 
investigations are needed to evaluate its role in the treatment 
of human infections due to MDR P. aeruginosa.
Monoclonal antibodies
Current research in the management of P. aeruginosa infec-
tion has been directed toward prevention of infection in 
high-risk patients with vaccines and modulation of virulence 
with monoclonal antibodies instead of focusing on bacterial 
clearance attainment. Its main appeal relies on multidrug 
therapy with one molecule targeting mechanisms of action 
of bacteria covering MDR strains and probably active in 
different infection models.
Monoclonal anti-type three secretion  
system antibodies 
Type three secretion system, known as TTSS or T3SS, is a 
complex system expressed by some bacteria which allows 
intoxication of host cells. This system is present in many 
gram-negative bacteria, including P. aeruginosa, and is based 
in several groups of proteins (more than 20) exhibited in the 
bacterial wall, which acts as a syringe, making the bacteria 
capable of injecting modulation factors and cytotoxins into 
other eukaryotic organisms, including the immune host appa-
ratus and epithelial cells, inducing cellular death and play-
ing an important role in P. aeruginosa virulence and in the 
inflammatory response.116–119 TTSS is a marker of virulence 
in P. aeruginosa penumonia110 and its presence in patients 
with VAP is associated with worse outcomes.119,120 TTSS 
plays an important role in VAP, since worse clinical outcomes 
are seen when TTSS is present. An obvious implication of 
this is that adjunctive therapies targeting these proteins, such 
as antibodies, may improve outcomes of patients under MV 
and P. aeruginosa respiratory isolation (both colonization and 
infection).119,121 The PcrV is a needle-tip protein involved in 
many steps of the TTSS-mediated infection process, sensing 
the outside environment and helping bacteria to recognize 
the strange cells. It also plays a role in translocation and 
secretion control of some proteins involved in functional 
molecular syringe assembling and facilitating the union into 
the molecular needle and the host membrane, which makes 
an attractive target in TTSS-mediated virulence control, 
with studies showing loss of virulence capacity in bacteria 
with an unfunctional PcrV, both in in vitro and in vivo ani-
mal models.116,121 Based on this idea, antibodies have been 
developed for the blockage of PcrV protein function, with 
many studies reporting a decrease in blood bacterial colonies 
and a less severe inflammatory response in various animal 
models treated with anti-PcrV immunoglobulins.117,122–124 
One of the most successful is the KB001, a high-affinity 
PEGylated Fab antibody, which, in a Phase II study, has been 
well tolerated and showed a safety profile in mechanically 
ventilated patients colonized by P. aeruginosa, also showing 
a nonstatistically significant tendency to reduce P. aeruginosa 
pneumonia episodes in the intervention group (Table 2).125
Monoclonal anti-alginate antibodies 
Alginate is involved in many processes during P. aeruginosa 
infection, providing protection against a variety of host 
defense mechanisms and environmental factors such as 
antimicrobial agents; it also is highly present in mucoid bio-
films and facilitates medical device colonization.105,107,126 This 
exopolysaccharide, principally exhibited by mucoid strains 
of P. aeruginosa, is capable of reducing the host immune 
response by interfering with the activation of complements 
and polymorphonuclear chemotaxis, and also was shown to 
play a role in decreasing the phagocytosis of Pseudomonas 
spp., both those that are planktonic and those that form bio-
film structure guaranteeing the P. aeruginosa survival during 
the first steps of primary infection, its permanency, and its 
chronic colonization development.105,107,127
Different monoclonal antibodies against alginate have 
been developed, showing an increase in P. aeruginosa phago-
cytosis. In some cases, as with the monoclonal  antibody F429, 
Table 2 Studies regarding the effect of adjunctive therapies on Pseudomonas aeruginosa infection
Authors Year Type of study Number  
of patients
Interventions Results
François et al125 2012 Multicenter, randomized,  
placebo-controlled,  
double-blind, Phase IIa
39 Single intravenous infusion  
of KB001 PeGylated Fab antibody  
(3 and 10 mg/kg)
was well tolerated and not 
immunogenic
Zaidi and Pier128 2008 experimental, murine  
model
NA Immunoglobulin G1 monoclonal  
antibody
Reduction of bacterial levels in the eye 
and the associated corneal pathology
Lu et al131 2011 Multicenter, open-label, 
pilot, Phase IIa
18 Panobacumab in three doses of  
1.2 mg/kg
was well tolerated and not 
immunogenic
Abbreviations: Fab, fragment antigen-binding; NA, not applicable.
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this improvement in immune response against P. aeruginosa 
infection was also reported in different models of infec-
tion such as pneumonia, sepsis, and keratitis in animal 
models,109,128 being promising as an adjunctive strategy in 
P. aeruginosa infection management (Table 2).
Panobacumab (AR-101)
Panobacumab is an IgM-type human monoclonal antibody 
that is directed against IATS 011 serotype P. aeruginosa, 
one of the most prevalent serotypes associated with noso-
comial pneumonia.16,129,130 A multicenter Phase II study 
using panobacumab in combination with different antip-
seudomonal antibiotics in critical patients with nosocomial 
pneumonia due to P. aeruginosa serotype O11, almost all 
with VAP, showed a good safety profile with good PKs 
(Table 1).131,132
Vaccines
P. aeruginosa’s infection mechanism and its interaction with 
the host immunity is highly studied and well known. With the 
advances in antimicrobial therapy and many sites identified as 
possible targets to improve the acquired immunity response 
and block the P. aeruginosa infection and biofilm formation, 
different types of vaccines are being designed to improve the 
immune response against many substances involved in this 
process. The most common targets are components of the 
bacterial surface, such as outer membrane proteins (Opr) 
and different polysaccharides (lipopolysaccharides, mucoid 
exopolysaccharide, and O-polysaccharides), structures 
involved in P. aeruginosa adhesion and movement, such as 
flagella, pili, and several virulence factors, such as TTSS, 
exotoxin A, or proteases.133,134 Development of an effec-
tive vaccine is difficult due to the high variability between 
Pseudomonas species and the complexity of its infection 
process and its interaction with the host immune response. 
In many cases during phase I, II and III studies, some mol-
ecules failed to provide an adequate coverage against different 
P. aeruginosa strains, or showed a low inmunogenicity capac-
ity or an unsecure profile.133–135
One of the most promising targets to induce an acquired 
immune response are the Opr, showing an improved immune 
response against P. aeruginosa infection in murine models 
previously exposed to modified epitopes from Opr.133,135,136 
From this group, the Opr-based vaccine IC43 has been used 
in healthy individuals and in different groups with increased 
risk to develop P. aeruginosa infection, including critical 
patients under MV, showing a good safety profile and being 
well tolerated,137–140 and there is an ongoing Phase II/III study 
designed to show its effect on mortality in mechanically 
ventilated ICU patients.141
Conclusion
P. aeruginosa VAP management requires prompt and 
adequate antibiotic exposure. Initial empiric therapy should 
be done with broad-spectrum antibiotics in combina-
tion therapy followed by de-escalation with one effective 
antibiotic since its effectiveness equals two antibiotics. 
Immunotherapy, including strategies with monoclonal 
antibodies, might be a new approach to treat (and perhaps 
prevent) P. aeruginosa infections. Future research should 
focus on optimizing outcomes with strategies of blocking 
virulence and vaccination.
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